From Wikipedia, the free encyclopedia
Pharmaceutical drug classification
Pharmaceutical drug classification
ATC code L04 Immunosuppressants is a therapeutic subgroup of the
Anatomical Therapeutic Chemical Classification System , a system of alphanumeric codes developed by the
World Health Organization (WHO) for the classification of
drugs and other medical products.
[1]
[2]
[3] Subgroup L04 is part of the anatomical group
L Antineoplastic and immunomodulating agents .
[4]
Codes for
veterinary use (
ATCvet codes ) can be created by placing the letter Q in front of the human ATC code: for example, QL04 .
[5] National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L04A Immunosuppressants
L04AA Selective immunosuppressants
L04AA03
Antilymphocyte immunoglobulin (horse)
L04AA04 Antithymocyte immunoglobulin (rabbit)
L04AA06
Mycophenolic acid
L04AA15
Alefacept
L04AA19
Gusperimus
L04AA22
Abetimus
L04AA24
Abatacept
L04AA28
Belatacept
L04AA32
Apremilast
L04AA40
Cladribine
L04AA41
Imlifidase
L04AA48
Belumosudil
L04AA58
Efgartigimod alfa
L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
L04AB01
Etanercept
L04AB02
Infliximab
L04AB03
Afelimomab
L04AB04
Adalimumab
L04AB05
Certolizumab pegol
L04AB06
Golimumab
L04AB07
Opinercept
L04AC Interleukin inhibitors
L04AC01
Daclizumab
L04AC02
Basiliximab
L04AC03
Anakinra
L04AC04
Rilonacept
L04AC05
Ustekinumab
L04AC07
Tocilizumab
L04AC08
Canakinumab
L04AC09
Briakinumab
L04AC10
Secukinumab
L04AC11
Siltuximab
L04AC12
Brodalumab
L04AC13
Ixekizumab
L04AC14
Sarilumab
L04AC15
Sirukumab
L04AC16
Guselkumab
L04AC17
Tildrakizumab
L04AC18
Risankizumab
L04AC19
Satralizumab
L04AC20
Netakimab
L04AC21
Bimekizumab
L04AC22
Spesolimab
L04AC23
Olokizumab
L04AD Calcineurin inhibitors
L04AD01
Ciclosporin
L04AD02
Tacrolimus
L04AD03
Voclosporin
L04AE Sphingosine 1-phosphate (S1P) receptor modulators
L04AE01
Fingolimod
L04AE02
Ozanimod
L04AE03
Siponimod
L04AE04
Ponesimod
L04AE05
Etrasimod
L04AF Janus-associated kinase (JAK) inhibitors
L04AF01
Tofacitinib
L04AF02
Baricitinib
L04AF03
Upadacitinib
L04AF04
Filgotinib
L04AF05
Itacitinib
L04AF06
Peficitinib
L04AF07
Deucravacitinib
L04AF08
Ritlecitinib
L04AG Monoclonal antibodies
L04AG01
Muromonab-CD3
L04AG02
Efalizumab
L04AG03
Natalizumab
L04AG04
Belimumab
L04AG05
Vedolizumab
L04AG06
Alemtuzumab
L04AG07
Begelomab
L04AG08
Ocrelizumab
L04AG09
Emapalumab
L04AG10
Inebilizumab
L04AG11
Anifrolumab
L04AG12
Ofatumumab
L04AG13
Teprotumumab
L04AG14
Ublituximab
L04AG15
Divozilimab
L04AG16
Rozanolixizumab
L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
L04AH01
Sirolimus
L04AH02
Everolimus
L04AJ Complement inhibitors
L04AJ01
Eculizumab
L04AJ02
Ravulizumab
L04AJ03
Pegcetacoplan
L04AJ04
Sutimlimab
L04AJ05
Avacopan
L04AJ06
Zilucoplan
L04AJ07
Crovalimab
L04AJ08
Iptacopan
L04AJ09
Danicopan
L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors
L04AK01
Leflunomide
L04AK02
Teriflunomide
L04AX Other immunosuppressants
L04AX01
Azathioprine
L04AX02
Thalidomide
L04AX03
Methotrexate
L04AX04
Lenalidomide
L04AX05
Pirfenidone
L04AX06
Pomalidomide
L04AX07
Dimethyl fumarate
L04AX08
Darvadstrocel
L04AX09
Diroximel fumarate
References
Intracellular (initiation)
Intracellular (reception)
Extracellular
Unsorted